JP2002524420A5 - - Google Patents

Download PDF

Info

Publication number
JP2002524420A5
JP2002524420A5 JP2000568509A JP2000568509A JP2002524420A5 JP 2002524420 A5 JP2002524420 A5 JP 2002524420A5 JP 2000568509 A JP2000568509 A JP 2000568509A JP 2000568509 A JP2000568509 A JP 2000568509A JP 2002524420 A5 JP2002524420 A5 JP 2002524420A5
Authority
JP
Japan
Prior art keywords
composition
unit dose
fgf
mutein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000568509A
Other languages
English (en)
Japanese (ja)
Other versions
JP5329729B2 (ja
JP2002524420A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/019770 external-priority patent/WO2000013701A2/en
Publication of JP2002524420A publication Critical patent/JP2002524420A/ja
Publication of JP2002524420A5 publication Critical patent/JP2002524420A5/ja
Application granted granted Critical
Publication of JP5329729B2 publication Critical patent/JP5329729B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000568509A 1998-09-03 1999-08-27 脈管形成に有効な単位用量のfgf−2および使用方法 Expired - Lifetime JP5329729B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14574398P 1998-09-03 1998-09-03
US10410398P 1998-10-13 1998-10-13
US10410298P 1998-10-13 1998-10-13
US60/104,102 1998-10-13
US60/104,103 1998-10-13
US60/145,743 1998-10-13
PCT/US1999/019770 WO2000013701A2 (en) 1998-09-03 1999-08-27 Angiogenically effective unit dose of fgf-2 and method of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010089915A Division JP2010163457A (ja) 1998-09-03 2010-04-08 脈管形成に有効な単位用量のfgf−2および使用方法

Publications (3)

Publication Number Publication Date
JP2002524420A JP2002524420A (ja) 2002-08-06
JP2002524420A5 true JP2002524420A5 (cg-RX-API-DMAC10.html) 2006-09-14
JP5329729B2 JP5329729B2 (ja) 2013-10-30

Family

ID=27379656

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000568509A Expired - Lifetime JP5329729B2 (ja) 1998-09-03 1999-08-27 脈管形成に有効な単位用量のfgf−2および使用方法
JP2010089915A Pending JP2010163457A (ja) 1998-09-03 2010-04-08 脈管形成に有効な単位用量のfgf−2および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010089915A Pending JP2010163457A (ja) 1998-09-03 2010-04-08 脈管形成に有効な単位用量のfgf−2および使用方法

Country Status (7)

Country Link
EP (2) EP1121142B1 (cg-RX-API-DMAC10.html)
JP (2) JP5329729B2 (cg-RX-API-DMAC10.html)
AT (2) ATE434440T1 (cg-RX-API-DMAC10.html)
AU (1) AU6022399A (cg-RX-API-DMAC10.html)
DE (2) DE69921348T2 (cg-RX-API-DMAC10.html)
ES (2) ES2327839T3 (cg-RX-API-DMAC10.html)
WO (1) WO2000013701A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6411199A (en) 1998-10-13 2000-05-01 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
US8618052B2 (en) 1998-10-13 2013-12-31 Novartis Vaccines And Diagnostics, Inc. Method of treating coronary artery disease by administering FGF-5
US20020072489A1 (en) 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
AU6634400A (en) 1999-08-13 2001-03-13 Chiron Corporation Dose of an angiogenic factor and method of administering to improve myocardial blood flow
US20020032153A1 (en) * 2000-03-10 2002-03-14 Whitehouse Martha Jo Methods and compositions for the treatment and prevention of erectile dysfunction
EP1894570A3 (en) * 2000-06-22 2009-11-11 Novartis Vaccines and Diagnostics, Inc. Methods and compositions for the treatment of peripheral artery disease
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
BRPI0922561A2 (pt) 2008-12-09 2020-08-11 Pfizer Vaccines Llc vacina de peptídeo de ch3 da ige.
EP3615560B1 (en) * 2017-04-26 2025-03-05 University of Cincinnati Fibroblast growth factor for use in treating patients unergoing ischemia-reperfusion therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
US4956455A (en) 1984-03-05 1990-09-11 The Salk Institute For Biological Studies Bovine fibroblast growth factor
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5439818A (en) 1985-09-12 1995-08-08 Scios Nova Inc. DNA encoding human recombinant basic fibroblast growth factor
EP0248819B2 (en) * 1985-09-12 2000-08-30 Scios Inc. Recombinant fibroblast growth factors
US5852177A (en) * 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins

Similar Documents

Publication Publication Date Title
JP2002527401A5 (cg-RX-API-DMAC10.html)
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
WO2000040086A1 (en) Formulations for treating disease and methods of using same
WO2002022163A1 (en) Remedies for ischemic diseases
Barnard et al. Bradycardia and the trigeminal nerve
Eron et al. Recurrence of condylomata acuminata following cryotherapy is not prevented by systemically administered interferon.
JP2002530353A5 (cg-RX-API-DMAC10.html)
WO2002058720A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
WO2000013701A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
JPH11246433A (ja) 心筋梗塞治療剤
WO1990004977A3 (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
Reisin et al. More rapid relief of pain with isosorbide dinitrate oral spray than with sublingual tablets in elderly patients with angina pectoris
Levy et al. Bepridil for recurrent sustained ventricular tachycardias: assessment using electrophysiologic testing
Lund-Olesen et al. Intra-articular orgotein therapy in osteoarthritis of the knee. A double-blind, placebo-controlled trial
WO1995009625A1 (en) Use of amiodarone for the treatment of heart failure
Heisel et al. Facilitating influence of procainamide on conversion of atrial flutter by rapid atrial pacing
JP2002529515A5 (cg-RX-API-DMAC10.html)
US4150119A (en) Method for treatment of vascular disease
Katz et al. Thrombolytic therapy for acute myocardial infarction in a 110-year-old man
WO2000043014A3 (en) Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections
Somberg et al. Antiarrhythmic action of bethanidine
JANUARY et al. Paroxysmal ventricular tachycardia treated with intravenous injections of quinidine
Murphy et al. Incessant atrial tachycardia accelerated by pregnancy
WO1997045114A1 (en) The treatment of vascular disease with prostaglandins via a sustained-release dermal patch
Rosano Coronary artery occlusion in medically treated patients with unstable angina. The importance of pre-existing coronary artery lesions and response to therapy